Application of phycocyanin in preparation of medicine for treating hypercholesterolemia

Abstract

The invention provides application of phycocyanin in preparation of a medicine for treating hypercholesterolemia, and belongs to the technical field of biology. Through establishment of a hypercholesterolemia mouse model and gavage of a phycocyanin solution, it is found that phycocyanin can reduce the weight, liver coefficient, blood TC content and LDL-C content of a hypercholesterolemia mouse, increase discharge of triglyceride in excrement and reduce the content of hemolytic phospholipid in the excrement; the result shows that the phycocyanin relieves the high cholesterol pressure of the mouse to a certain extent. The invention has important research significance and value for researching the hypercholesterolemia on the treatment of organism-related diseases and complications.

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to the application of phycocyanin in the preparation of drugs for treating hypercholesterolemia. Background Art

[0002] Hypercholesterolemia is an important risk factor for cardiovascular diseases (such as atherosclerosis, coronary heart disease and stroke), and its morbidity and mortality rates are increasing year by year worldwide. According to statistics from the World Health Organization (WHO), cardiovascular disease is one of the leading causes of death worldwide, and hypercholesterolemia is a key preventable risk factor.

[0003] Currently, the treatment of hypercholesterolemia mainly relies on statins, which reduce blood cholesterol levels by inhibiting key enzymes in the cholesterol synthesis pathway (HMG-CoA reductase). However, long-term use of statins may lead to a series of side effects, such as abnormal liver function, muscle pain, and increased risk of diabetes. In addition, some patients are intolerant to statins or have poor treatment effects. Therefore, the development of safe, effective and naturally derived alternative or auxiliary treatments has become the focus of current research.

[0004] Phycocyanin is a water-soluble pigment protein extracted from cyanobacteria such as Spirulina, which has unique blue and fluorescent properties. In recent years, phycocyanin has attracted widespread attention due to its various biological activities, including antioxidant, anti-inflammatory, immunomodulatory and anti-tumor effects. In recent years, with the in-depth study of the biological activity of phycocyanin, people have found that phycocyanin has antioxidant, liver and kidney protection, immunity enhancement and anti-tumor effects. Whether phycocyanin has the effect of treating hypercholesterolemia has not been reported. Summary of the invention

[0005] In view of this, the purpose of the present invention is to provide the use of phycocyanin in the preparation of a drug for treating hypercholesterolemia, thereby providing a new idea for the treatment of hypercholesterolemia.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] Application of phycocyanin in the preparation of drugs for treating hypercholesterolemia.

[0008] Preferably, the A620 / A280 of the phycocyanin is ≥4.

[0009] More preferably, the phycocyanin is prepared by using spirulina powder as raw material, extracting the phycocyanin crude extract by ultrasonic crushing, and then purifying the crude extract by DEAE-cellulose column ion exchange and hydroxyapatite (HA) column affinity chromatography.

[0010] More preferably, the ultrasonic crushing comprises the following steps: taking spirulina powder, adding 0.01-0.05 mol / L PBS, ultrasonically treating for 3-10 min, repeating 3-4 times, and then centrifuging at 5000-10000 r / min for 20-40 min to obtain a crude phycocyanin extract; the PBS has a pH of 5-6 and contains 0.01-0.1 mol / L NaCl; the power of the ultrasonic treatment is 50-200 W, and the amplitude is 20%-50%.

[0011] More preferably, the DEAE-cellulose column ion exchange and hydroxyapatite (HA) column affinity chromatography purification comprises the following steps: equilibrating the DEAE pre-loaded column with 0.01-0.05 mol / L PBS, loading the phycocyanin crude extract, washing away the unadsorbed protein, and then, under weak light conditions, using 0.01-0.05 mol / L PBS and 0.1-0.3 mol / L NaH2PO4 for linear gradient elution at a flow rate of 0.5-2 mL / min, and collecting the elution peak; the PBS The pH value is 5-6, containing 0.01-0.1mol / LNaCl; the NaH2PO4 pH value is 4-5, containing 0.1-0.3mol / LNaCl; the elution peak is dialyzed into 0.005-0.02mol / LPBS, and the hydroxyapatite pre-packed column is equilibrated with 0.005-0.02mol / LPBS, and the dialyzed phycocyanin eluate is loaded, and after washing away the unadsorbed protein, 0.4-0.6mol / LPBS is used for linear gradient elution under weak light conditions, and the flow rate is 0.3-1mL / min, and the elution peak is collected to obtain purified phycocyanin; the PBS pH value is 6.5-7.5, and contains 0.1-0.3mol / LNaCl.

[0012] Preferably, the phycocyanin is capable of controlling body weight.

[0013] Preferably, the phycocyanin is capable of reducing liver index.

[0014] Preferably, the phycocyanin can reduce the total cholesterol TC content and the low-density cholesterol LDL-C content in the blood.

[0015] Preferably, the phycocyanin can increase the excretion of triglycerides in feces and reduce the content of lysophospholipids in feces.

[0016] The present invention also provides a drug for treating hypercholesterolemia, wherein the active ingredient is phycocyanin; the A620 / A280 of the phycocyanin is ≥4, and the content is ≥100 mg / mL.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] The present invention reveals for the first time that phycocyanin improves hypercholesterolemia by regulating the comprehensive pathway of lipid absorption, metabolism and excretion, providing a new scientific basis for its application in the treatment of cardiovascular diseases. Phycocyanin is extracted from Spirulina and is a natural bioactive substance with excellent biocompatibility. No obvious toxic side effects were observed during the experiment, making it suitable for long-term treatment.

[0019] Phycocyanin can significantly reduce the blood total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels of hypercholesterolemia mice, and avoid the side effects of long-term use of statins such as abnormal liver function and muscle pain, providing patients with a safer alternative or auxiliary treatment plan. Phycocyanin not only works by inhibiting cholesterol absorption, but also promotes the excretion of lipid metabolism in vitro by increasing the excretion of triglycerides in feces, while reducing the content of lysophospholipids in feces, thereby alleviating lipid metabolism disorders in multiple dimensions. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The SDS-PAGE electrophoresis diagram of the phycocyanin prepared by the present invention and the phycocyanin samples at different stages, in which 1 and 5 are protein markers, 2 is the crude extract of phycocyanin, 3 is the DEAE flow-through solution, 4 is the DEAE eluate, 6 is the dialyzed DEAE eluate, 7 is the HA flow-through solution, and 8 is the purified phycocyanin;

[0021] Figure 2 This is the body weight change of C57BL / 6 mouse model;

[0022] Figure 3 The weight changes of C57BL / 6 mouse model after oral gavage;

[0023] Figure 4 The changes of liver coefficient and fat pad coefficient of C57BL / 6 mouse model after oral gavage;

[0024] Figure 5 The changes of blood indexes in C57BL / 6 mouse model after intragastric administration;

[0025] Figure 6 The figure shows the changes in lipid indicators in the feces of C57BL / 6 mouse model after oral gavage. In the figure, a is the normal group, b is the high-fat model group, and c is the phycocyanin group. DETAILED DESCRIPTION

[0026] The present invention provides application of phycocyanin in preparing medicine for treating hypercholesterolemia.

[0027] In the present invention, the A620 / A280 of the phycocyanin is preferably ≥ 4, and more preferably A620 / A280 is 4.15.

[0028] In the present invention, preferably, phycocyanin is extracted from spirulina powder by ultrasonic crushing to obtain a crude extract of phycocyanin, and then purified by DEAE-cellulose column ion exchange and hydroxyapatite (HA) column affinity chromatography. In the present invention, preferably, ultrasonic crushing includes the following steps: taking spirulina powder, adding 0.01-0.05mol / LPBS, more preferably 0.02mol / LPBS; ultrasonic treatment for 3-10min, more preferably 5min; repeating 3-4 times, more preferably 3 times; then centrifuging at 5000-10000r / min for 20-40min to obtain a crude extract of phycocyanin, more preferably 8000r / min for 30min. Preferably, PBS has a pH of 5-6, containing 0.01-0.1mol / LNaCl, more preferably a pH of 5.6, containing 0.05mol / LNaCl. Preferably, the power of ultrasonic treatment is 50-200W, more preferably 100W, and the amplitude is 20%-50%, more preferably 30%.

[0029] In the present invention, preferably, DEAE-cellulose column ion exchange and hydroxyapatite (HA) column affinity chromatography purification comprises the following steps: equilibrate the DEAE pre-loaded column with 0.01-0.05mol / LPBS, more preferably 0.02mol / LPBS; load the phycocyanin crude extract, wash away the unadsorbed protein, and then use 0.01-0.05mol / LPBS and 0.1-0.3mol / LNaH2PO4 for linear gradient elution under weak light conditions, more preferably 0.02mol / L PBS and 0.2mol / L NaH2PO4; flow rate is 0.5-2mL / min, more preferably 1mL / min; collect elution peak. Preferably, PBS pH is 5-6, containing 0.01-0.1mol / LNaCl, more preferably pH 5.6, containing 0.05mol / LNaCl. Preferably, the pH of NaH2PO4 is 4-5, containing 0.1-0.3 mol / L NaCl, and more preferably, the pH is 4.1, containing 0.2 mol / L NaCl.

[0030] The elution peak is dialyzed into 0.005-0.02mol / LPBS, and the hydroxyapatite pre-packed column is balanced with 0.005-0.02mol / LPBS, and 0.01mol / LPBS is more preferably used; the dialyzed phycocyanin eluate is loaded, and after washing away the unadsorbed protein, 0.4-0.6mol / LPBS is used for linear gradient elution under weak light conditions, and 0.5mol / LPBS is more preferably used; the flow rate is 0.3-1mL / min, and 0.5mL / min is more preferably used; the elution peak is collected to obtain purified phycocyanin. Preferably, the PBS pH is 6.5-7.5, containing 0.1-0.3mol / LNaCl, and more preferably pH 7.0, containing 0.2mol / LNaCl.

[0031] The purified phycocyanin prepared by the present invention is used to treat hypercholesterolemia, can control body weight, reduce liver coefficient, reduce total cholesterol TC content and low-density cholesterol LDL-C content in blood, increase the excretion of triglycerides in feces, and reduce the content of lysophospholipids in feces.

[0032] The present invention also provides a drug for treating hypercholesterolemia, wherein the active ingredient is phycocyanin; the A620 / A280 of the phycocyanin is ≥4, preferably 4.15, and further preferably the phycocyanin content is ≥100 mg / mL.

[0033] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0034] In the following examples, spirulina powder was provided by Lijiang Chenghai Paul Biotechnology Co., Ltd. Male C57BL / 6 mice weighing about 20 g were purchased from Zhejiang Experimental Animal Center; the feeding environment was good, without known pollutants, and they were free to eat and drink water. Ordinary standard feed was purchased from Zhejiang Experimental Animal Center; 60% rod-shaped high-fat feed (TP23400) was purchased from Nantong Trophy Feed Technology Co., Ltd.; the kits used for the detection of 4 blood indicators [triglycerides (TG), total cholesterol (TC), high-density lipoprotein (LDL-C) and low-density lipoprotein (LDL-C)] were purchased from Nanjing Jiancheng Bioengineering Research Institute; other reagents were purchased from Sinopharm Chemical Reagent Co., Ltd. The electronic balance was purchased from Mettler-Toledo XS105DU; the ultrasonic disruptor was purchased from Ningbo Xinzhi Biotechnology Co., Ltd.; the protein purifier pure 25 was purchased from GE, USA; the constant temperature incubator was purchased from Shanghai Yiheng Scientific Instrument Co., Ltd.; the microplate reader SepctraMax Paradigm was purchased from Thermo Corporation, USA; and the Q-Exactive electrostatic field orbital trap high-resolution mass spectrometer was purchased from ThermoFisher, USA.

[0035] Example 1

[0036] Preparation of Phycocyanin

[0037] Take Spirulina powder, add 0.02 mol / L phosphate buffer PBS (pH 5.6, containing 0.05 mol / L NaCl); ultrasonic treatment for 5 min (power 100 W, amplitude 30%), repeat 3 times, and then centrifuge at 8000 r / min for 30 min to obtain a crude phycocyanin extract.

[0038] The DEAE prepacked column was equilibrated with 0.02 mol / L PBS (pH 5.6, containing 0.05 mol / L NaCl), the crude phycocyanin extract was loaded, and after washing away the unadsorbed protein, 0.02 mol / L PBS (pH 5.6, containing 0.05 mol / L NaCl) and 0.2 mol / L NaH2PO4 (pH 4.1, containing 0.2 mol / L NaCl) were used for linear gradient elution under weak light conditions at a flow rate of 1 mL / min, and the elution peak was collected.

[0039] The elution peak was dialyzed into 0.01mol / LPBS (pH 7.0, containing 0.2mol / LNaCl), and the hydroxyapatite HA pre-packed column was equilibrated with 0.01mol / LPBS (pH7.0, containing 0.2mol / LNaCl), and the dialyzed phycocyanin eluate was loaded, and after washing away the unadsorbed protein, 0.5mol / LPBS (pH 7.0, containing 0.2mol / LNaCl) was used under weak light conditions at a flow rate of 0.5mL / min to collect the elution peak to obtain purified phycocyanin.

[0040] Example 2

[0041] Phycocyanin purity test

[0042] The crude phycocyanin extract, DEAE flow-through, DEAE eluate, dialyzed DEAE eluate, HA flow-through and purified phycocyanin of Example 1 were collected as samples and detected by 12% SDS-PAGE gel electrophoresis. The A620 and A280 values ​​of the phycocyanin solutions at different treatment stages were measured, and the A620 / A280 value was calculated. The higher the A620 / A280 value, the higher the purity.

[0043] According to Table 1, the purity of phycocyanin is the highest after purification by DEAE and HA. Figure 1 As shown, the purified phycocyanin obtained two bands by 12% SDS-PAGE electrophoresis, corresponding to the two subunits α and β of the protein, with molecular masses of 17.0 kD±0.7 kD and 21.4 kD±1.0 kD, respectively.

[0044] Table 1 Phycocyanin crude extract and purity of purified phycocyanin

[0045] deal with Phycocyanin crude extract DEAE eluent HA eluate A620 / A280 0.57 1.58 4.15

[0046] Example 3

[0047] Hyperlipidemia mouse model test

[0048] 1. Establishment of C57BL / 6 hyperlipidemia mouse model

[0049] C57BL / 6 mice grouping: 50 male mice were randomly divided into 2 groups, 10 in the normal group and 40 in the high-fat group. Each group was fed with corresponding feed, free drinking water, and corn litter was changed once a week for 8 consecutive weeks. The weight of the mice was weighed and the data was recorded every week.

[0050] 2. Gavage Experiment

[0051] After 10 weeks of continuous feeding, the mice in the high-fat group were subdivided into 2 groups, 20 mice in each group: a high-fat model group and a phycocyanin group.

[0052] The mice in the normal group were fed with standard feed and had free access to water; the high-fat model group and the phycocyanin group (PC) were fed with 60% rod-shaped high-fat feed and had free access to water; in addition, the phycocyanin group was gavaged with 100 μL of the purified phycocyanin solution (100 mg / mL, dissolved in saline) prepared in Example 1, and the high-fat model group was gavaged with 100 μL of saline every day; gavage was continued for 4 weeks, and the mice were weighed and the data were recorded every week.

[0053] 3. Blood physiological and biochemical tests

[0054] After 4 weeks of continuous gavage, the mice were dissected, and the liver and fat weights of the mice were weighed and recorded. The blood of the mice was collected and placed in a 4°C refrigerator for 8 hours, and the plasma was collected by centrifugation at 3000g. The TC, TG, LDL-C, and HDL-C detection kits were used to measure various blood indicators.

[0055] 4. Analysis of Mouse Fecal Lipid Metabolism

[0056] Weigh 10 mg of freeze-dried fecal samples from each group of mice, add a 1:1 chloroform / methanol (V / V) mixed solution to extract total lipids, blow dry with nitrogen, re-dissolve in methanol, centrifuge and filter through a 0.22 μm ultrafiltration membrane (Mil-lipore, USA), and then perform LC-MS / MS analysis. 50 μg / mL butylated hydroxytoluene BHT was added to all solvents. The lipidomics of mouse feces was studied using a Q-Exactive electrostatic field orbital trap high-resolution mass spectrometer, and the analysis method was as follows:

[0057] The liquid phase is DionexTM UltiMate TM U3000 reverse phase liquid chromatograph, chromatographic column is ACQUITY UPLCRBEH C8 (100mm×2.1mm, 1.7μm, Waters, USA), sample injection volume is 3μL. Mobile phase A: acetonitrile / water (6:4, V / V), mobile phase B: isopropanol / acetonitrile (9:1, V / V). 0.1% formic acid and 0.05% ammonia water were added to mobile phases A and B as auxiliary ionization agents, and the flow rate was 0.2ml / min. The elution program was: 0-15min, 60-45% A; 15.0-18.0min, 45-35% A; 18.0-26.0min, 35% A; 26.0-28.0min, 35-0% A; 28.0-30.0min, 0% A; 30.0-30.5min, return to the initial gradient 60% A; 30.5-40min, 60% A, and the column was equilibrated under the initial conditions for 10min. The mass spectrometer used was a Q-Exactive electrostatic field orbital trap high-resolution mass spectrometer, an electrospray ionization source (HESI-II), and a mass range of m / z 200-2000. The mass spectrometer was operated in data-dependent acquisition mode (FullMS-ddMS2), and automatically switched between MS and MS / MS acquisition. Full scan spectra were obtained at a resolution of 70,000, and HCD MS / MS scans were performed at a resolution of 17,500. Automatic gain control (AGC) target value 1e 6 MS, 2e 5 MS 2 ; Spray voltage was 3.5KV, ion transfer tube temperature was 350℃, sheath gas pressure was 45arb, auxiliary gas pressure was 10arb, vaporization chamber temperature was 350℃; high energy collision was selected for secondary mass spectrometry, collision energy was 25, 30V in positive ion mode, and collision energy was 20, 24, 28V in negative ion mode. The instrument was calibrated for positive and negative ions before sample operation.

[0058] 5. Data Analysis

[0059] The lipidomics data were analyzed using SIMCA-P 14.1 (Umetrics, Umea, Sweden) software. After Pareto-scaling preprocessing, unsupervised principal component analysis (PCA), least squares discriminant analysis (PLS-DA) and orthogonal partial least squares discriminant analysis (OPLS-DA) were performed to screen out differential metabolic markers. SPSS25.0 software was used to perform statistical analysis on the data of each group. The data results of each group were expressed as Mean±SD. One-way ANOVA was performed between groups. Post hoc test was performed using Studentt test for pairwise comparison and significance analysis. Two-tailed P<0.05 indicated that the difference was statistically significant. # P<0.01, indicating a significant difference compared with the normal group; ## P<0.001, indicating a very significant difference compared with the normal group; * P<0.05, indicating a significant difference compared with the high-fat model group; ** P<0.01, indicating a very significant difference compared with the high-fat model group.

[0060] 6. Test results:

[0061] (1) Body weight changes of C57BL / 6 mice

[0062] Body weight changes of C57BL / 6 mice Figure 2 As shown, compared with the normal group, the weight gain of C57BL / 6 mice in the high-fat group was significantly faster, with significant differences from the 2nd to the 4th week and extremely significant differences after the 5th week.

[0063] (2) Changes in body weight of mice in each group before and after oral gavage

[0064] The changes in body weight of C57BL / 6 mice before and after oral gavage are shown in Figure 2. Figure 3 As shown. Figure 3 It can be seen that before oral gavage, the body weight of the high-fat model group, the phycocyanin group and the normal group was significantly different, while the difference between the high-fat model group and the phycocyanin group was not significant; 4 weeks after oral gavage, the body weight of the phycocyanin group was significantly reduced compared with the high-fat model group.

[0065] (3) Changes in liver coefficient and fat pad coefficient

[0066] Changes in liver coefficient and fat pad coefficient of C57BL / 6 mouse model after intragastric administration Figure 4 As shown. Figure 4It can be seen that after 4 weeks of intragastric administration, the liver coefficient of the phycocyanin group did not change significantly compared with the high-fat model group, but was significantly lower than that of the normal group. The fat pad coefficients of the phycocyanin group and the high-fat model group were significantly increased compared with the normal group.

[0067] (4) Changes of blood indexes in each group after intragastric administration

[0068] Blood changes in the C57BL / 6 mouse model after intragastric administration Figure 5 As shown. Figure 5 It can be seen that after 4 weeks of intragastric administration, the total cholesterol (TC) in the phycocyanin group and the high-fat model group was significantly increased compared with the normal group, but the phycocyanin group was significantly decreased compared with the high-fat model group. The triglycerides (TG) in the phycocyanin group and the high-fat model group were significantly increased compared with the normal group, but there was no significant difference between the phycocyanin group and the high-fat model group. The low-density cholesterol (LDL-C) in the phycocyanin group and the high-fat model group was significantly increased compared with the normal group, but the phycocyanin group was significantly decreased compared with the high-fat model group. The high-density cholesterol (HDL-C) in the phycocyanin group and the high-fat model group was significantly increased compared with the normal group, but there was no significant change between the phycocyanin group and the high-fat model group.

[0069] (5) Fecal lipid metabolism

[0070] Changes in fecal lipid metabolism in C57BL / 6 mouse model after intragastric administration Figure 6 As shown. Figure 6 It can be seen that after 4 weeks of intragastric administration, the contents of three triglycerides, TG (18:0e / 18:1 / 18:1), TG (18:0p / 18:1 / 18:1), and TG (18:0e / 18:1 / 18:2), were compared and it was found that the high-fat model group did not change much compared with the normal group, but the phycocyanin group was significantly increased compared with the high-fat model group and the normal group. In addition, the lysophosphatidylcholine LPC (15:0), LPC (16:0), LPC (18:0) and lysophosphatidylethanolamine LPE (18:0) in the phycocyanin group showed a downward trend compared with the high-fat model group. The above results show that phycocyanin can reduce the absorption of triglycerides by regulating the metabolism of mice.

[0071] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of phycocyanin in the preparation of drugs for the treatment of hypercholesterolemia.

2. The use according to claim 1, characterized in that: The A620 / A280 of the phycocyanin is ≥4.

3. The use according to claim 1 or 2, characterized in that: The phycocyanin is prepared by using spirulina powder as raw material, extracting phycocyanin crude extract by ultrasonic crushing, and then purifying by DEAE-cellulose column ion exchange and hydroxyapatite column affinity chromatography.

4. The use according to claim 3, characterized in that: The ultrasonic crushing comprises the following steps: taking spirulina powder, adding 0.01-0.05 mol / L PBS, ultrasonically treating for 3-10 min, repeating 3-4 times, and then centrifuging at 5000-10000 r / min for 20-40 min to obtain a crude phycocyanin extract; the pH value of the PBS is 5-6 and contains 0.01-0.1 mol / L NaCl; the power of the ultrasonic treatment is 50-200 W and the amplitude is 20%-50%.

5. The use according to claim 3, characterized in that: The DEAE-cellulose column ion exchange and hydroxyapatite column affinity chromatography purification comprises the following steps: equilibrating the DEAE pre-packed column with 0.01-0.05 mol / L PBS, loading the phycocyanin crude extract, washing away the unadsorbed protein, and then, under weak light conditions, using 0.01-0.05 mol / L PBS and 0.1-0.3 mol / L NaH2PO4 for linear gradient elution at a flow rate of 0.5-2 mL / min, and collecting the elution peak; the PBS has a pH of 5-6 and contains 0.01-0.1 mol / L NaCl; the NaH2PO4 has a pH of 4-5 and contains 0.1-0.3 mol / L NaCl; The elution peak is dialyzed into 0.005-0.02mol / LPBS, and a hydroxyapatite pre-packed column is equilibrated with 0.005-0.02mol / LPBS. The dialyzed phycocyanin eluate is loaded, and after washing away the unadsorbed protein, 0.4-0.6mol / LPBS is used for linear gradient elution under weak light conditions at a flow rate of 0.3-1mL / min. The elution peak is collected to obtain purified phycocyanin; the PBS has a pH of 6.5-7.5 and contains 0.1-0.3mol / LNaC1.

6. The use according to claim 1, characterized in that: The phycocyanin can control body weight.

7. The use according to claim 1, characterized in that: The phycocyanin can reduce the liver index.

8. The use according to claim 1, characterized in that: The phycocyanin can reduce the total cholesterol TC content and the low-density cholesterol LDL-C content in the blood.

9. The use according to claim 1, characterized in that: The phycocyanin can increase the excretion of triglyceride in feces and reduce the content of lysophospholipid in feces.

10. A drug for treating hypercholesterolemia, characterized in that: The active ingredient of the drug is phycocyanin; the A620 / A280 of the phycocyanin is ≥4, and the content is ≥100 mg / mL.

Images